All In Biotech

Drug Trial Radar · NCT00078325

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Feb 2004

Primary completion

Nov 2004

Study completion Nov 2004

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
Feb 25, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit.

Conditions

  • Obstructive Sleep Apnea
  • Hypopnea

Interventions

  • Armodafinil 250 mg/dayDrug

    Armodafinil 250 mg once daily in the morning

  • Armodafinil 150 mg/dayDrug

    Armodafinil 150 mg once daily in the morning

  • PlaceboDrug

    Matching placebo tablets once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintenance of Wakefulness Test (MWT)Time frame: change from baseline at 12 weeks
  2. Clinical Global Impression of Change (CGI-C)Time frame: change from baseline at 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.